An example of this is the SUMMIT-HF study [7] with Tirzepatide, where patients with an apparently correct diagnosis of HFpEF had NT-proBNP levels of 196 pg/mL and 169 pg/mL in the Tirzepatide and placebo groups, respectively. This evidence concerns the gene NPPB and hydrops fetalis.